Correlation Between Mereo BioPharma and Pyxis Oncology

Can any of the company-specific risk be diversified away by investing in both Mereo BioPharma and Pyxis Oncology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mereo BioPharma and Pyxis Oncology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mereo BioPharma Group and Pyxis Oncology, you can compare the effects of market volatilities on Mereo BioPharma and Pyxis Oncology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mereo BioPharma with a short position of Pyxis Oncology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mereo BioPharma and Pyxis Oncology.

Diversification Opportunities for Mereo BioPharma and Pyxis Oncology

0.87

Correlation Coefficient

Mereo BioPharma  Pyxis Oncology

Very poor diversification

The 3 months correlation between Mereo and Pyxis is 0.87. Overlapping area represents the amount of risk that can be diversified away by holding Mereo BioPharma Group and Pyxis Oncology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pyxis Oncology and Mereo BioPharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mereo BioPharma Group are associated (or correlated) with Pyxis Oncology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pyxis Oncology has no effect on the direction of Mereo BioPharma i.e., Mereo BioPharma and Pyxis Oncology go up and down completely randomly.

Pair Corralation between Mereo BioPharma and Pyxis Oncology

Given the investment horizon of 90 days Mereo BioPharma Group is expected to under-perform the Pyxis Oncology. But the stock apears to be less risky and, when comparing its historical volatility, Mereo BioPharma Group is 1.13 times less risky than Pyxis Oncology. The stock trades about -0.19 of its potential returns per unit of risk. The Pyxis Oncology is currently generating about -0.14 of returns per unit of risk over similar time horizon. If you would invest  159.00  in Pyxis Oncology on December 27, 2024 and sell it today you would lose (52.00) from holding Pyxis Oncology or give up 32.7% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	98.36%
Values	Daily Returns

Mereo BioPharma Group  vs.  Pyxis Oncology

Mereo BioPharma Group

Risk-Adjusted Performance

Very Weak

Over the last 90 days Mereo BioPharma Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pyxis Oncology

Risk-Adjusted Performance

Very Weak

Over the last 90 days Pyxis Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Mereo BioPharma and Pyxis Oncology

The main advantage of trading using opposite Mereo BioPharma and Pyxis Oncology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mereo BioPharma position performs unexpectedly, Pyxis Oncology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pyxis Oncology will offset losses from the drop in Pyxis Oncology's long position.

The idea behind Mereo BioPharma Group and Pyxis Oncology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.